New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1
Thursday, 11 February 2021
BellBrook scientist Meera Kumar and Robert Lowery were recently published in SLAS Discovery for their work entitled Development of a High-Throughput Assay to Identify Inhibitors of ENPP1. Ectonucleotide pyrophosphatase/phosphodiesterase 1 or ENNP1 has recently become a target for cancer immunotherapy. ENNP1 hydrolyzes nucleotides such as cGAMP and ATP. Cytosolic DNA is a trigger for the
- Published in Emerging Targets, HTS Assays, News
No Comments
Using a Universal GMP Assay for PDE Research
Thursday, 28 January 2021
A universal GMP assay to aid in PDE research and potential COVID-19 disruption. – Phosphodiesterase enzymes (PDEs) modulate pathways throughout the body. Since unregulated PDEs contribute to disease in many cases, it makes sense therapies that inhibit these enzymes have the potential to treat several different ailments. These include cardiovascular and respiratory issues, diabetes, fibrotic
- Published in HTS Assays, Uncategorized
ST6GAL1 Drug Discovery to Combat Cancer
Wednesday, 08 January 2020
The number of cancer hallmarks has increased as the knowledge and understanding of the disease progress. As many of us already know, the basic characteristic is a mutation that causes uncontrollable cell growth causing a tumor. Cancer is truly a multi-step development that enables cells to survive, proliferate and metastasize. Other hallmarks of the disease
- Published in Emerging Targets, HTS Assays
Helping Fight Ovarian Cancer with ST3GAL1 Inhibitors
Monday, 11 November 2019
Important functions such as cell–cell recognition, protein targeting, and cell adhesion taking place in the human body get carried out through a process known as sialylation. Sialylation is a common reaction that is catalyzed by a sialyltransferase (ST) enzyme with the goal of adding a sialic acid (monosaccharide) to a growing oligosaccharide forming a glycolipid
- Published in HTS Assays
ENPP1 Inhibitors, Assays, and Innate Immunity
Wednesday, 16 October 2019
The human immune response is incredible. Unlike the adaptive immune response, the innate response acts quickly and is considered the first line of defense against pathogens and foreign DNA such as tumor cells. To be effective, the innate immune response relies on several cell types and a multitude of proteins such as interferons (INFs). This
- Published in Emerging Targets
How A PDE Activity Assay Might Help Find New Treatments for Individuals Suffering from Heart Disease
Tuesday, 06 August 2019
Heart Disease: The Role of PDEs and a PDE Activity Assay Heart disease is often misunderstood due to confusion with terminology and the different types of heart disease that exist. While a heart attack can occur quickly, heart failure is a slower progression where the heart weakens over time. One thing is certain; heart disease
- Published in HTS Assays
Ubiquitin Ligase Assay: A Handy Tool for Drug Discovery
Wednesday, 29 May 2019
Can one cellular pathway contribute to many different types of disease? Research has shown that Ubiquitination is one such pathway due to its role in the regulation of protein degradation within homeostasis, cell cycle, and DNA repair. It has been established that at least the following diseases are among those affected from alterations in this
- Published in Emerging Targets, HTS Assays
Could an Inhibitor of Phosphodiesterase Activity be a Treatment for Alzheimer’s?
Tuesday, 14 May 2019
As we continue to increase our lifespan, diseases such as Alzheimer’s will subsequently persist to develop. With up to 4.5 million Americans currently affected, there’s a strong desire to find a cure or at the very least some relief from the symptoms.¹ Neurodegeneration derived memory loss is the most common and perhaps the most devastating result
- Published in Emerging Targets, HTS Assays
Immuno-Oncology Drug Discovery: A CD39 Activity Assay for a Promising Target
Thursday, 02 May 2019
What comes to mind when you think of immunotherapy? The immune system, with all its complexities, contributes to numerous diseases that affect our society. It’s no wonder scientists scramble to find therapies that will either suppress (suppression immunotherapies) or activate (activation immunotherapies) an immune response. Immunotherapy isn’t only used for autoimmune diseases or infectious disease.
- Published in Emerging Targets, HTS Assays
Visit With BellBrook Labs at Discovery On Target 2018
Tuesday, 04 September 2018
BellBrook Labs will exhibit and present posters at the upcoming Discovery on Target conference in Boston, MA. At the event BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, methyltransferase activity measurement, studying ectonucleotidase enzymes, screening for kinase inhibitors, and more! Discovery on Target 2018 Sheraton Boston Hotel
- Published in News